Company profile ARCT
Arcturus Therapeutics Holdings Inc
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team wit...h extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.
Show More
After 39 days of this quarter the interest is at 49.0. Based on that we can calculate that during remaining 52 days it will total up to 114.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 44 | 96 118.2% QoQ | 47 -51.0% QoQ | 38 -19.1% QoQ |
| 2020 | 140 218.2% YoY 268.4% QoQ | 349 263.5% YoY 149.3% QoQ | 269 472.3% YoY -22.9% QoQ | 315 728.9% YoY 17.1% QoQ |
| 2021 | 198 41.4% YoY -37.1% QoQ | 115 -67.0% YoY -41.9% QoQ | 129 -52.0% YoY 12.2% QoQ | 130 -58.7% YoY 0.8% QoQ |
| 2022 | 77 -61.1% YoY -40.8% QoQ | 150 30.4% YoY 94.8% QoQ | 117 -9.3% YoY -22.0% QoQ | 107 -17.7% YoY -8.5% QoQ |
| 2023 | 111 44.2% YoY 3.7% QoQ | 157 4.7% YoY 41.4% QoQ | 182 55.6% YoY 15.9% QoQ | 135 26.2% YoY -25.8% QoQ |
| 2024 | 49 -55.9% YoY -63.7% QoQ | - | - | - |
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
The average 5 years interest of Arcturus Therapeutics -stock -company was 11.32 per week. The last year interest of Arcturus Therapeutics -stock -company compared to the last 5 years has changed by 2.74%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 132.6%.
Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ARCT
Earnings date: 2024-02-26 After close
Company name: Arcturus Therapeutics Holdings Inc
Sector: Manufacturing
Company's websiteHyperchartsYahoo FinanceMarketWatchStockTwitsSEC FilingsSwaggyStocksLatest articles
2026-10-09T12:27:56.828773547Z
Analyst Upgrades
Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $192026-09-24T15:47:23.179936048Z
Analyst Upgrades
Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $202026-09-24T09:39:31.504866553Z
Analyst Upgrades
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $202026-09-23T16:30:00-04:00
Earnings Call Transcripts
ARCTURUS PRESENTATION - ARCTURUS THERAPEUTICS HOLDINGS INC2026-09-23T20:01:00Z
BusinessWire
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform2026-09-18T13:00:00Z
BusinessWire
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform2026-08-31T20:01:00Z
BusinessWire
Arcturus Therapeutics to Participate in Upcoming Investor Conferences2026-08-06T20:01:00Z
BusinessWire
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress2026-07-28T20:01:00Z
BusinessWire
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 20262026-07-20T20:01:00Z
BusinessWire
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference2026-07-02T13:35:29.025267338Z
Analyst Upgrades
This Adobe Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday2026-07-02T11:21:19.821636638Z
Analyst Upgrades
This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday2026-07-02T11:00:00Z
BusinessWire
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis2026-07-02T09:47:42.477512546Z
Analyst Upgrades
Freedom Broker Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $272026-05-26T20:01:00Z
BusinessWire
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference